Obermatt
See Similar Stocks →

Flags

Earnings warning

Liquidia Corporation

NAQ:LQDA · US53635D2027
PharmaceuticalsSmall

360

70
EV / EBIT69
Price / Owner Earnings1
Owner Earnings Yield10
Dividend Yield1
Price/Sales55
EV / Gross Profit1
Price/Book20
Return on Capital73
Cash Return on Capital71
Return on Equity91
EBIT Margin34
Gross Profitability94
Cash Conversion84
Accruals89
Owner Earnings Margin15
Sales growth93
Profit growth96
Reinvestment44
Price momentum90
Debt load20
Refinancing72
Debt Payback100
Liquidity77
Analyst ratings87
Opinion Changes10
Price Target Upside8
Market mood84
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Liquidia Corporation generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2020
Employees189
Websiteliquidia.com
ISINUS53635D2027
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
3D PrintingPulmonologyRespiratoryCardiovascularBiopharmaNanotechnologyTherapeutics

Description

Liquidia Corporation (Liquidia) operates as a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, such as pulmonary arterial hypertension (PAH) and pulmonar…

Analysis

Beloved champion

Liquidia Corporation is a beloved champion: its quality is genuine, and the market already prices it as exceptional.

The price is expensive. You pay 383.9× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is solid and the balance sheet is adequate. The company scores 20/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
77
2023202420252026

All-time high

77

Jun 2026

All-time low

15

Jan 2025

Average rank

53

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
55
3
13
15
Price/Earnings
17
28
28
28
Price/Book
20
11
7
26
Dividend Yield
1
1
1
1
Value (overall)
11
10
8
9

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Liquidia Corporation with its peers
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tarsus Pharmaceuticals
NSQ:TARS
29
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Johnson & Johnson
NYQ:JNJ
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Cognition Therapeutics
NAQ:CGTX
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Milestone Pharmaceuticals
NSQ:MIST
4
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
LENZ Therapeutics
NSQ:LENZ
11
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →